Amgen Can't Dodge Kickback Claims In Aranesp Suit

Law360, Washington (August 26, 2011, 7:35 PM EDT) -- Amgen Inc. on Friday lost a bid for summary judgment in a Massachusetts whistleblower suit alleging the company and others bribed health care providers to purchase Aranesp, but ruled that the company had appropriately calculated the average sale price of the anemia drug.

Relator Kassie Westmoreland accuses her former employer Amgen and International Nephrology Network, ASD Healthcare, AmerisourceBergen Corp. and AmerisourceBergen Specialty Group of giving kickbacks to health care providers to buy Aranesp.

“Amgen properly did not account for overfill in calculating Aranesp's average sales price,”...
To view the full article, register now.